Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Prima BioMed Ltd IMMP

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
48.72
Revenue
—
Net Income
0.00
Free Cash Flow
(57.40)
Net Debt
(64.76)
Current Ratio
2.97
Debt/Equity
0.01
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
0.54
Past 5Y EPS Growth
9.98%
This Y EPS Growth
74.47%
Next Y EPS Growth
(7.44%)
Next 5Y EPS Growth
31.96%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—

Assets vs Liabilities

2023 2024 2025 2026
Cash 83.08 119.27 84.00 46.74
Receivables 5.35 4.82 6.39 6.39
Inventory — — — —
Other 2.42 1.39 6.17 1.59
90.86 125.49 96.56 54.72
2023 2024 2025 2026
Payables 6.08 6.27 6.89 9.10
ST’ Debt — — 0.72 —
Other — — — —
6.58 6.88 8.26 9.61
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’26 — — — —
16.40
’25 — — — —
6.69
’24 — — — —
5.14
’23 — — — —
3.50
’22 — — — —
4.90
’21 — — — —
2.97
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’26 — — — (18.81)
(37.64)
’25 — — — (18.60)
(40.18)
’24 — — — (12.02)
(22.84)
’23 — — — (7.84)
(23.80)
’22 — — — (8.59)
(21.93)
’21 — — — (6.61)
(13.18)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’26 — — — (18.87)
(37.71)
’25 — — — (18.75)
(40.36)
’24 — — — (12.24)
(23.45)
’23 — — — (7.89)
(23.86)
’22 — — — (8.59)
(21.95)
’21 — — — (6.61)
(13.19)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 — — — —
—
’26 — — — —
(0.37)
’25 — — — —
(0.27)
’24 — — — —
(0.23)
’23 — — — —
(0.30)
’22 — — — —
(0.27)
’21 — — — —
(0.38)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ 1.47 1.50 1.66 1.32 0.28 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.64 3.90 3.34 3.53 3.23 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 35 35 44 51 — — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.14 0.10 0.12 0.13 0.00 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.90 3.50 5.14 6.69 16.40 — — —
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (23.37) (26.86) (28.01) (39.78) (53.82) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (476.62%) (767.22%) (544.95%) (594.64%) (328.13%) — — —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ (23.37) (26.86) (28.01) (39.78) (53.82) — — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — 1.50 1.39 1.48 1.55 1.68 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.06 0.04 0.04 0.05 0.11 — — —
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.27) (0.30) (0.23) (0.27) (0.37) — — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.26) (0.27) (0.19) (0.28) (0.26) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 (0.01) 0.00 0.00 — — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.26) (0.27) (0.20) (0.28) (0.26) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.80 1.03 1.03 0.64 0.28 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 84.90 89.24 120.11 145.58 147.16 — — —
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ — — — — — — — — —
PE Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 0.00 — — —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.97 5.08 3.24 1.77 0.79 — — —
PB Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 0.00 — — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.12) (7.99) (5.08) (2.05) 0.23 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.93) (23.80) (22.84) (40.18) (37.64) — — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.02) (0.06) (0.61) (0.18) (0.06) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.95) (23.86) (23.45) (40.36) (37.71) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 61.23 84.28 118.61 88.29 45.11 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.05 0.56 0.63 0.72 — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (56.98) (82.52) (118.64) (83.28) (46.74) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 68.25 91.87 124.29 93.02 41.76 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ (34.51%) (30.98%) (24.21%) (34.02%) (68.06%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (128.28%) (178.93%) (309.31%) (248.37%) 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.00%) (33.55%) (25.92%) (36.62%) (79.87%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Prima BioMed Ltd (IMMP) dazzles with headlines on its lead cancer immunotherapy eftilagimod alpha (efti), from promising Phase IIb data doubling progression-free survival in breast cancer to combo trials with Merck’s Keytruda. Yet, beneath the biotech hype lurks a decade of red flags: relentless cash burn, explosive share dilution up 551% since 2016, and profitability that’s a persistent mirage. Revenues spike on milestone payments—like the 107% surge to $11.1 million in 2020—only to crater 73% the next year amid trial delays, clawing back modestly to $5.14 million in 2024 without denting deepening losses, now ballooning 41% to -$28 million EBT.

Efficiency metrics scream inefficiency: revenue per employee eroded 69% from peaks amid headcount bloat, while free cash flow per share worsens 42% to -$0.277 by 2025 forecasts, torching a 2-3 year runway without more dilution. ROE and ROIC stay mired in negative territory, value destruction unchecked, as stock prices swing wildly on binary trial news—1,400% ranges in 2020—decoupling from eroding fundamentals like slashed book value per share.

Analysts dream of 235% upside on Phase III hopes and buyouts, but contrarians see a high-risk gamble: 90%+ biotech attrition, insider silence post-wins, and history of flops like Novartis ditching efti’s predecessor. Prima’s no moonshot—it’s a dilution-fueled survival act begging for a short amid the hype.

Read full commentary →

Prima BioMed Ltd (IMMP) Latest News

News by impact score

Fine-tune

11 Sep

3 , 8:00 AM
Immutep outlines focused development strategy for eftilagimod alfa to advance its clinical programs. Refined efti development plan may streamline trials and resource use without immediate major shifts.

13 Jul

4 , 8:00 AM
Immutep reported positive mature overall survival data from the INSIGHT-003 trial in first-line NSCLC along with an update from the TACTI-004 study. Positive NSCLC survival data from two trials can materially advance Immutep's clinical pipeline and investor outlook.

4 Jun

4 GlobeNewswire, 8:00 AM
Immutep will present positive interim Phase I data for IMP761, a first-in-class LAG-3 agonist antibody, at EULAR 2026. Positive Phase I data on first-in-class pipeline asset signals major clinical progress that can shift company trajectory and sentiment.

28 May

4 GlobeNewswire, 8:00 AM
Prima BioMed Ltd's eftilagimod alfa triggers systemic immune activation tied to statistically significant gains in overall survival among late-stage cancer patients. Positive survival data from eftilagimod alfa trials can materially lift investor sentiment and advance Prima BioMed's clinical pipeline.

10 May

3 Simply Wall St., 6:03 PM
Immutep (ASX:IMM) shows strong potential to deliver growth plans via Phase III eftilagimod alpha trials, key partnerships like with Merck, cash runway to mid-2026, and expanding pipeline despite high R&D burn. Growth plans assessment highlights pipeline progress and finances that moderately boost investor sentiment without transformative shifts.

30 Apr

4 GlobeNewswire, 8:00 AM
Immutep Limited (NASDAQ: IMMP), formerly Prima BioMed Ltd, received a Nasdaq notice of bid price deficiency after its shares traded below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance by achieving a $1.00 closing bid price for 10 consecutive days, or face delisting risk. Nasdaq bid price deficiency notice creates delisting risk that significantly pressures stock price, liquidity, and investor sentiment.

3 GlobeNewswire, 8:00 AM
Immutep (Prima BioMed Ltd, IMMP) released its Quarterly Activities Report for Q3 FY26, covering progress in clinical trials, partnerships, and operational updates. Quarterly activities reports detail clinical advancements and strategic developments that moderately influence biotech investor sentiment and trajectory.

22 Apr

3 GlobeNewswire, 8:00 AM
Immutep announces abstract acceptance for presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. ASCO abstract acceptance signals clinical trial progress and visibility, moderately boosting investor sentiment on pipeline without major trajectory changes.

20 Apr

4 , 10:47 PM
Immutep Limited (IMMP) receives FDA Orphan Drug Designation for efti in soft tissue sarcoma. FDA Orphan Drug Designation grants seven years of market exclusivity, tax credits, and protocol assistance, providing significant regulatory and commercial advantages for efti in treating rare soft tissue sarcoma.

15 Apr

4 GlobeNewswire, 8:00 AM
Immutep receives FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, granting benefits including seven years of market exclusivity upon approval, tax credits, and regulatory fee waivers. FDA Orphan Drug Designation provides key incentives like market exclusivity and fee waivers that accelerate development and enhance investor sentiment for eftilagimod alfa in a rare cancer indication.

19 Mar

3 GlobeNewswire, 8:00 AM
Immutep reports progress from Phase I study of LAG-3 agonist targeting autoimmune diseases. Phase I progress validates early safety of LAG-3 agonist in autoimmune diseases but lacks efficacy data to drive major trajectory shifts.

13 Mar

5 www.clinicaltrialsarena.com, 3:02 PM
Immutep terminates Phase III trial for NSCLC, severely impacting its LAG-3 program prospects. Phase III NSCLC trial termination fundamentally jeopardizes Immutep's core LAG-3 asset and long-term viability.

5 GlobeNewswire, 8:00 AM
Prima BioMed Ltd (IMMP) to discontinue TACTI-004 Phase III study in first-line NSCLC following futility analysis showing low probability of meeting primary endpoint. Discontinuation of a pivotal Phase III trial due to futility halts key pipeline progress and severely damages Prima BioMed's prospects.

9 Feb

3 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 3:48 PM
Immutep Limited (ASX:IMM) is primarily controlled by institutional shareholders, who collectively own 50% of the company. This significant ownership stake indicates a strong influence of institutional investors on the company's strategic decisions and governance. Institutional ownership may moderately influence the company's strategic direction and market perception.

6 Feb

4 GlobeNewswire, 8:00 AM
Immutep has reached 50% enrollment in its global TACTI-004 (KEYNOTE-F91) Phase III trial, which is investigating the efficacy of its lead product candidate, eftilagimod alpha, in combination with pembrolizumab for first-line treatment of non-small cell lung cancer (NSCLC). This milestone is a significant step in the trial, which aims to evaluate the safety and effectiveness of the treatment regimen in patients with advanced NSCLC. The trial's progress is expected to provide valuable data that could influence future treatment options and market positioning for Immutep. Achieving 50% enrollment in a pivotal Phase III trial is a significant milestone that could impact future product development and market dynamics.

29 Jan

3 GlobeNewswire, 8:00 AM
Prima BioMed Ltd (IMMP) reported its quarterly activities for Q2 FY26, highlighting advancements in clinical trials and product development. The company continues to focus on its lead immunotherapy candidate, with ongoing studies aimed at enhancing treatment efficacy. Financial updates indicate a stable cash position, supporting ongoing research initiatives. Collaborations with strategic partners are also emphasized, aiming to expand market reach and innovation in therapeutic solutions. Ongoing clinical trials and product development may moderately influence financial performance and competitive positioning.

21 Jan

3 transcript www.marketbeat.com, 12:14 PM
Dr. Reddy's Laboratories reported its Q3 earnings, highlighting key financial metrics and strategic initiatives. The company demonstrated growth in revenue and net profit, driven by strong performance in its core segments. Management discussed ongoing product launches and pipeline developments, emphasizing their commitment to innovation and market expansion. The earnings call also addressed challenges faced in certain markets and outlined plans to mitigate risks moving forward. The earnings report indicates moderate growth and strategic initiatives that could influence market positioning.

13 Jan

3 Simply Wall St., 3:02 PM
Prima BioMed Ltd (IMMP) is highlighted among ASX penny stocks, alongside Immutep and two others, as potential investment opportunities. The article discusses the company's recent developments and market positioning, suggesting that it may be worth considering for investors looking at lower-priced stocks in the biotech sector. Recent developments may moderately influence investor sentiment and market performance.

22 Dec

4 GlobeNewswireInsider MonkeyMT NewswiresInsider MonkeyMT NewswiresMT NewswiresMT NewswiresMT Newswires, 8:00 AM
Immutep has announced positive results from a Phase I study of IMP761, a first-in-class LAG-3 agonist antibody aimed at treating autoimmune diseases. The study demonstrated promising safety and tolerability profiles, along with early signs of efficacy. These findings support the potential of IMP761 as a novel therapeutic option for patients with autoimmune conditions, marking a significant step forward in the development of this treatment. Positive Phase I results for IMP761 could significantly enhance the company's product pipeline and market position in autoimmune therapies.

16 Dec

4 GlobeNewswire, 8:00 AM
Immutep has reported strong operational progress in its global TACTI-004 (KEYNOTE-F91) Phase III clinical trial, with patient enrollment continuing at a robust pace. The trial aims to evaluate the efficacy of Immutep's lead product candidate, eftilagimod alpha, in combination with pembrolizumab for treating patients with non-small cell lung cancer. The company remains optimistic about the trial's potential impact on its future prospects. The ongoing Phase III trial represents a significant strategic move that could greatly influence Immutep's market position and investor sentiment.

15 Dec

4 Simply Wall St., 2:36 PM
Prima BioMed Ltd (IMMP) is highlighted as a high-growth tech stock to watch in December 2025, reflecting its potential in the biotechnology sector. The company is recognized for its innovative approaches and advancements in medical technology, which may position it favorably in the market. Investors are encouraged to monitor its developments closely as it navigates the competitive landscape. Significant advancements in biotechnology and potential market shifts could greatly influence Prima BioMed's future performance.

4 Insider Monkey, 12:35 PM
Immutep (IMMP) has announced a strategic partnership with an Indian firm, which is expected to enhance its market presence and operational capabilities. This collaboration aims to leverage the strengths of both companies in the biopharmaceutical sector, potentially leading to innovative developments in immunotherapy. The deal signifies a positive step for IMMP as it seeks to expand its reach and impact in the industry. The partnership is likely to significantly enhance IMMP's market position and operational capabilities, impacting future performance.

10 Dec

4 Insider Monkey, 2:13 PM
Immutep Limited (IMMP) has reported positive data from its clinical trials, indicating promising results for its immunotherapy treatments. The trials focused on the efficacy and safety of the company's lead product candidates, which are aimed at treating various cancers. This positive outcome is expected to enhance the company's position in the competitive biopharmaceutical market and may lead to further development and commercialization opportunities. Positive trial results are likely to significantly impact future product development and investor sentiment.

8 Dec

4 ReutersInsider MonkeyMT NewswiresSouth China Morning Post, 11:15 AM
Dr. Reddy's Laboratories has entered into a licensing agreement with Immutep to market and sell Immutep's cancer drug, eftilagimod alpha, in India. This partnership aims to enhance the availability of innovative cancer therapies in the Indian market, leveraging Dr. Reddy's established distribution network. The agreement is expected to facilitate the development and commercialization of the drug, which is currently undergoing clinical trials for various cancer indications. This collaboration signifies a strategic move for both companies in the competitive oncology landscape. The licensing agreement represents a significant strategic partnership that could enhance market presence and revenue potential for both companies in the oncology sector.

4 GlobeNewswirePharmaceutical TechnologyMT NewswiresPharmaceutical TechnologyMotley FoolMT NewswiresMT NewswiresMT Newswires, 8:00 AM
Immutep and Dr. Reddy’s have entered into a strategic collaboration to commercialize Eftilagimod Alfa, an innovative oncology drug. This partnership aims to leverage Dr. Reddy’s expertise in drug development and commercialization to enhance the market presence of Eftilagimod Alfa, which is designed to treat various cancers. The collaboration is expected to accelerate the drug's availability to patients and expand its reach in the oncology market. The collaboration represents a significant strategic move that could enhance market positioning and financial performance for Prima BioMed Ltd.

7 Dec

3 , 2:35 PM
Prima BioMed Ltd (IMMP) is highlighted among three high-growth tech stocks in Australia, showcasing its potential in the biotech sector. The company focuses on innovative therapies and has been gaining attention for its advancements in immunotherapy. Investors are encouraged to consider IMMP as part of a diversified portfolio, given its promising developments and the overall growth trajectory of the biotech industry in Australia. The company's advancements in immunotherapy may moderately influence its financial performance and competitive positioning.

2 Dec

4 GlobeNewswire, 8:00 AM
Immutep will present new data from the AIPAC-003 Phase II clinical trial at the 2025 San Antonio Breast Cancer Symposium. This presentation is expected to provide insights into the efficacy and safety of Immutep's product in treating breast cancer, potentially influencing future research and development strategies. The presentation of new clinical trial data could significantly impact investor sentiment and the company's strategic direction in oncology.

3 Simply Wall St., 2:34 PM
Prima BioMed Ltd (IMMP) is highlighted among three ASX stocks potentially trading significantly below their intrinsic value estimates, with a noted undervaluation of up to 41.6%. This suggests that the stock may present a buying opportunity for investors looking for value in the market. Analysts are evaluating the company's fundamentals and market position to determine its future performance and potential for recovery. The stock's undervaluation indicates a moderately noticeable influence on its future performance and market sentiment.

1 Dec

4 Simply Wall St., 2:35 PM
Prima BioMed Ltd (IMMP) is highlighted as a high-growth tech stock in Australia, showcasing its potential in the biotechnology sector. The company focuses on innovative therapies and has made significant advancements in its product pipeline. Investors are encouraged to monitor IMMP due to its promising developments and the overall growth trajectory of the biotech industry in Australia. Significant advancements in product development and market positioning are likely to impact future performance.

26 Nov

4 Simply Wall St., 2:35 PM
Prima BioMed Ltd (IMMP) is highlighted as one of the high-growth tech stocks in Australia for November 2025, reflecting its strong market position and potential for future growth. The company is recognized for its innovative approaches in the biotech sector, which may lead to significant advancements and investor interest. Analysts suggest that IMMP's strategic initiatives and product developments could enhance its competitive edge in the market, making it a noteworthy investment opportunity. Significant strategic initiatives and product developments are expected to enhance the company's competitive position.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us